Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT00691015
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 204
- Registration Number
- NCT00683046
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
HD Melphalan and SCT in Patients With IGDD or LCDD
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT00681044
- Locations
- 🇺🇸
Boston University Cancer Research Center, Boston, Massachusetts, United States
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00679367
- Locations
- 🇺🇸
Boston University Cancer Research Center, Boston, Massachusetts, United States
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
- Conditions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 60
- Registration Number
- NCT00669812
- Locations
- 🇬🇧
Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00661544
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
- Conditions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Duke University
- Registration Number
- NCT00661336
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00651937
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00641030
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
- Conditions
- Childhood Soft Tissue SarcomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood MedulloblastomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsChildhood Central Nervous System Germ Cell TumorEwing SarcomaOvarian Mixed Germ Cell TumorRecurrent Ovarian Germ Cell TumorUnspecified Adult Solid Tumor, Protocol SpecificPreviously Untreated Childhood Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00638898
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.